Susan Rienow of Pfizer confirmed as next President of the ABPI

The ABPI Board has confirmed that Susan Rienow, UK Country President of Pfizer, will be the next President of the Association of the British Pharmaceutical Industry (ABPI).

Our industry is developing a new generation of medicines and vaccines, and I look forward to working with colleagues across the industry, Government and the NHS to ensure these can transform the lives of patients across the country. Susan Rienow, ABPI President-Elect

Susan was appointed as ABPI Vice-President in September 2022 and will formally take up her role as President in May 2023. As President, Susan will lead the ABPI Board to deliver the organisations mission to make the UK the best place in the world to research, develop and use new medicines and vaccines.

At Pfizer, Susan leads the organisation across the breadth of Pfizer’s innovative medicines and vaccines portfolio. She previously led Pfizer UK’s Vaccines business unit during the COVID-19 pandemic.

Commenting on her appointment, Susan said:

“I’m delighted to be taking up the role of ABPI President at such a huge moment of opportunity for both the UK and our industry.

“The Government has set out a bold ambition to be a science superpower, and with a new Department for Science, Innovation and Technology, I believe that the industry and Government can drive this agenda together to deliver long term economic growth.

“Our industry is developing a new generation of medicines and vaccines, and I look forward to working with colleagues across the industry, Government and the NHS to ensure these can help transform the lives of people across the country”.

Last modified: 26 April 2024

Last reviewed: 26 April 2024

The ABPI exists to make the UK the best place in the world to research, develop and use new medicines. We represent companies of all sizes who invest in discovering the medicines of the future. 

Our members supply cutting edge treatments that improve and save the lives of millions of people. We work in partnership with Government and the NHS so patients can get new treatments faster and the NHS can plan how much it spends on medicines. Every day, we partner with organisations in the life sciences community and beyond to transform lives across the UK.